Healio

Proposed biosimilar shows equivalence to golimumab in rheumatoid arthritis

Please provide your email address to receive an email when new articles are posted on . Alvotech’s AVT05 showed therapeutic equivalence with golimumab in DAS28-CRP score change at 16 weeks. The ...
Nasdaq

Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of Alvotech’s ...
JD Supra

Alvotech and Teva Announce Acceptance of BLA for AVT05, a Golimumab Biosimilar

On January 27, 2025, Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar to SIMPONI and SIMPONI ARIA. This marks the first U.S. BLA ...
Healio

Biosimilars as effective as originator drugs in rheumatoid arthritis treatment

Please provide your email address to receive an email when new articles are posted on . Monoclonal antibodies decrease inflammation in the immune system by binding to ...
Seeking Alpha

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...